We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GlaxoSmithKline and Vir’s Monoclonal Antibody Enters Phase 3 COVID-19 Trials
GlaxoSmithKline and Vir’s Monoclonal Antibody Enters Phase 3 COVID-19 Trials
GlaxoSmithKline (GSK) and Vir Biotechnology have begun enrolling participants in phase 3 trials to assess the safety and efficacy of their monoclonal antibody, VIR-7831, in treating COVID-19 infections early on in high-risk patients.